^
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    orelabrutinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    zanubrutinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    temsirolimus
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    ibrutinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    rituximab + bortezomib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    acalabrutinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    bortezomib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    avapritinib
    Sensitive: A1 - Approval
    No biomarker
    Mantle Cell Lymphoma
    venetoclax + ibrutinib
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    bendamustine
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    rituximab + lenalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    venetoclax
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    rituximab + ibrutinib + lenalidomide
    Sensitive: A2 - Guideline
    ALK negative
    Mantle Cell Lymphoma
    brentuximab vedotin
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    VR-CAP
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    R-DHAP
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    R-DHAX
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    R-CVAD
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    R-GemOx
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    venetoclax + rituximab
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: A2 - Guideline
    CCR7 positive
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive: B - Late Trials
    ABCB1 mutation + VEGFA mutation
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    VEGFA mutation
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    ABCB1 mutation
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    No biomarker
    Mantle Cell Lymphoma
    INCB50465
    Sensitive: B - Late Trials
    CCND1 overexpression
    Mantle Cell Lymphoma
    INCB50465
    Sensitive: C2 – Inclusion Criteria
    TP53 mutation
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: C2 – Inclusion Criteria
    TP53 mutation
    Mantle Cell Lymphoma
    venetoclax + obinutuzumab + zanubrutinib
    Sensitive: C2 – Inclusion Criteria
    NLRC5 mutation
    Mantle Cell Lymphoma
    acalabrutinib
    Resistant: C3 – Early Trials
    B2M mutation
    Mantle Cell Lymphoma
    acalabrutinib
    Resistant: C3 – Early Trials
    CARD11 mutation
    Mantle Cell Lymphoma
    acalabrutinib
    Resistant: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    rituximab + ibrutinib + lenalidomide
    Sensitive: C3 – Early Trials
    PD-L1 underexpression
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    CDKN2A deletion
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    Immunotherapy + lenalidomide
    Resistant: C3 – Early Trials
    ATM mutation
    Mantle Cell Lymphoma
    venetoclax + ibrutinib
    Sensitive: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    venetoclax + ibrutinib
    Sensitive: C3 – Early Trials
    PRMT5 overexpression + MTAP deletion
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    CDKN2A deletion + MTAP deletion
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    HES1 overexpression
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    SOX11 expression
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    CTLA4 overexpression
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    ITK overexpression
    Mantle Cell Lymphoma
    rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    R-CHOP
    Resistant: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    NOTCH1 mutation
    Mantle Cell Lymphoma
    ibrutinib
    Resistant: C3 – Early Trials
    ARID1B deletion
    Mantle Cell Lymphoma
    temsirolimus
    Resistant: C3 – Early Trials
    DLGAP2 deletion
    Mantle Cell Lymphoma
    temsirolimus
    Resistant: C3 – Early Trials
    BIRC3 mutation
    Mantle Cell Lymphoma
    temsirolimus
    Resistant: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    rituximab + lenalidomide
    Sensitive: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    venetoclax + rituximab + lenalidomide
    Sensitive: C3 – Early Trials
    CD20 positive
    Mantle Cell Lymphoma
    GEN3013
    Sensitive: C3 – Early Trials
    TP53 overexpression
    Mantle Cell Lymphoma
    ibrutinib
    Sensitive: C3 – Early Trials
    Chr t(11;14)
    Mantle Cell Lymphoma
    INCB50465
    Sensitive: C3 – Early Trials
    TP53 deletion
    Mantle Cell Lymphoma
    venetoclax + rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    TP53 mutation
    Mantle Cell Lymphoma
    venetoclax + rituximab + ibrutinib
    Sensitive: C3 – Early Trials
    TP53 mutation + CARD11 mutation + SMARCA4 mutation
    Mantle Cell Lymphoma
    venetoclax + obinutuzumab + zanubrutinib
    Sensitive: C4 – Case Studies
    PIK3CD expression
    Mantle Cell Lymphoma
    BI 6727
    Sensitive: D – Preclinical
    ROR1 expression
    Mantle Cell Lymphoma
    MK-2140
    Sensitive: D – Preclinical
    MYC overexpression
    Mantle Cell Lymphoma
    TG-1701
    Sensitive: D – Preclinical
    IL6 elevation
    Mantle Cell Lymphoma
    TG-1701
    Sensitive: D – Preclinical
    IL2 elevation
    Mantle Cell Lymphoma
    TG-1701
    Sensitive: D – Preclinical
    IL2 elevation
    Mantle Cell Lymphoma
    umbralisib + TG-1701 + ublituximab
    Sensitive: D – Preclinical
    IL6 elevation
    Mantle Cell Lymphoma
    umbralisib + TG-1701 + ublituximab
    Sensitive: D – Preclinical
    TNFA elevation
    Mantle Cell Lymphoma
    umbralisib + TG-1701 + ublituximab
    Sensitive: D – Preclinical
    LY9 expression
    Mantle Cell Lymphoma
    T-lymphocyte cell therapy
    Sensitive: D – Preclinical
    BTK C481S
    Mantle Cell Lymphoma
    TG-1701
    Sensitive: D – Preclinical
    PIK3CG expression
    Mantle Cell Lymphoma
    copanlisib
    Sensitive: D – Preclinical
    PIK3CG expression
    Mantle Cell Lymphoma
    BI 6727
    Sensitive: D – Preclinical
    PIK3CG expression
    Mantle Cell Lymphoma
    copanlisib + BI 6727
    Sensitive: D – Preclinical
    PIK3CD expression
    Mantle Cell Lymphoma
    copanlisib
    Sensitive: D – Preclinical
    PIK3CD expression
    Mantle Cell Lymphoma
    copanlisib + BI 6727
    Sensitive: D – Preclinical
    PIK3CB expression
    Mantle Cell Lymphoma
    copanlisib
    Sensitive: D – Preclinical
    PIK3CB expression
    Mantle Cell Lymphoma
    BI 6727
    Sensitive: D – Preclinical
    PIK3CB expression
    Mantle Cell Lymphoma
    copanlisib + BI 6727
    Sensitive: D – Preclinical
    PIK3CA expression
    Mantle Cell Lymphoma
    copanlisib
    Sensitive: D – Preclinical
    PIK3CA expression
    Mantle Cell Lymphoma
    copanlisib + BI 6727
    Sensitive: D – Preclinical
    PIK3CA expression
    Mantle Cell Lymphoma
    BI 6727
    Sensitive: D – Preclinical
    BCL2L1 overexpression
    Mantle Cell Lymphoma
    venetoclax
    Resistant: D – Preclinical
    SYK overexpression
    Mantle Cell Lymphoma
    piceatannol
    Sensitive: D – Preclinical
    TP53 deletion
    Mantle Cell Lymphoma
    venetoclax
    Resistant: D – Preclinical
    CCND1 expression
    Mantle Cell Lymphoma
    palbociclib
    Sensitive: D – Preclinical
    ATM underexpression
    Mantle Cell Lymphoma
    olaparib
    Sensitive: D – Preclinical
    CCND1 expression + CDK4 expression
    Mantle Cell Lymphoma
    palbociclib
    Sensitive: D – Preclinical
    NOTCH1 mutation
    Mantle Cell Lymphoma
    Compound E
    Sensitive: D – Preclinical
    SAMHD1 mutation
    Mantle Cell Lymphoma
    fludarabine IV
    Resistant: D – Preclinical
    SAMHD1 mutation
    Mantle Cell Lymphoma
    cytarabine
    Resistant: D – Preclinical